- Conditions
- Follicular Lymphoma, Marginal Zone Lymphoma, Indolent Non-hodgkin Lymphoma
- Interventions
- Obinutuzumab, Glofitamab
- Drug
- Lead sponsor
- Reid Merryman, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–3
of 3
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Follicular Lymphoma, Low Grade Non-Hodgkin's Lymphoma, Adult
- Interventions
- Epcoritamab, Rituximab
- Drug
- Lead sponsor
- Reid Merryman, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 6
- States / cities
- Boston, Massachusetts • New York, New York • Rochester, New York + 2 more
- Conditions
- Follicular Lymphoma, Lymphoma, Non-Hodgkin Lymphoma, Relapsed Lymphoma, Refractory Lymphoma, Marginal Zone Lymphoma
- Interventions
- Zanubrutinib, Rituximab, Epcoritamab
- Drug
- Lead sponsor
- Reid Merryman, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • New York, New York • Columbus, Ohio